Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease

Detalhes bibliográficos
Autor(a) principal: Gomes, Luis Eduardo Miani
Data de Publicação: 2019
Outros Autores: Silva, Francesca Aparecida Ramos da, Pascoal, Lı´via Bitencourt, Ricci, Renato Lazarin, Nogueira, Guilherme, Camargo, Michel Gardere, Ayrizono, Maria de Lourdes Setsuko, Fagundes, João José, Leal, Raquel Franco
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/157947
Resumo: OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) as well as the detection of anti-infliximab antibodies (ATIs) in patients with Crohn’s disease (CD). METHOD: Forty patients with CD under treatment at a tertiary center in southeastern Brazil were evaluated. Their use of infliximab was continuous and regular. We analyzed and compared the differences in the IFX and ATI levels between the patients with active CD (CDA) and those with CD in remission (CDR). RESULTS: There was no difference in the IFX level between the CDA and CDR groups (p40.05). Eighty percent of all patients had IFX levels above the therapeutic concentration (6-10 mg/mL). Two (9%) of the 22 patients with active disease and four (22.2%) of the 18 patients in remission had undetectable levels of IFX. Four (66.6%) of the six patients with undetectable levels of IFX had positive ATI levels; three of these patients were in remission, and one had active disease. In addition, the other two patients with undetectable levels of IFX presented ATI levels close to positivity (2.7 and 2.8 AU/ml). None of the patients with therapeutic or supratherapeutic IFX levels had positive ATI levels. CONCLUSIONS: The undetectable levels of IFX correlated with the detection of ATIs, which was independent of disease activity. Immunogenicity was not the main factor for the loss of response to IFX in our study, and the majority of patients in both groups (CDA and CDR) had supratherapeutic levels of IFX.
id USP-19_407db1fa5b4d433af9a4bfa96514ceab
oai_identifier_str oai:revistas.usp.br:article/157947
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s DiseaseCrohn’s DiseaseInfliximabAntibodyDrug MonitoringOBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) as well as the detection of anti-infliximab antibodies (ATIs) in patients with Crohn’s disease (CD). METHOD: Forty patients with CD under treatment at a tertiary center in southeastern Brazil were evaluated. Their use of infliximab was continuous and regular. We analyzed and compared the differences in the IFX and ATI levels between the patients with active CD (CDA) and those with CD in remission (CDR). RESULTS: There was no difference in the IFX level between the CDA and CDR groups (p40.05). Eighty percent of all patients had IFX levels above the therapeutic concentration (6-10 mg/mL). Two (9%) of the 22 patients with active disease and four (22.2%) of the 18 patients in remission had undetectable levels of IFX. Four (66.6%) of the six patients with undetectable levels of IFX had positive ATI levels; three of these patients were in remission, and one had active disease. In addition, the other two patients with undetectable levels of IFX presented ATI levels close to positivity (2.7 and 2.8 AU/ml). None of the patients with therapeutic or supratherapeutic IFX levels had positive ATI levels. CONCLUSIONS: The undetectable levels of IFX correlated with the detection of ATIs, which was independent of disease activity. Immunogenicity was not the main factor for the loss of response to IFX in our study, and the majority of patients in both groups (CDA and CDR) had supratherapeutic levels of IFX.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2019-05-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/15794710.6061/clinics/2019/e824Clinics; Vol. 74 (2019); e824Clinics; v. 74 (2019); e824Clinics; Vol. 74 (2019); e8241980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/157947/153226https://www.revistas.usp.br/clinics/article/view/157947/153575Copyright (c) 2019 Clinicsinfo:eu-repo/semantics/openAccessGomes, Luis Eduardo MianiSilva, Francesca Aparecida Ramos daPascoal, Lı´via BitencourtRicci, Renato LazarinNogueira, GuilhermeCamargo, Michel GardereAyrizono, Maria de Lourdes SetsukoFagundes, João JoséLeal, Raquel Franco2019-05-24T13:16:00Zoai:revistas.usp.br:article/157947Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2019-05-24T13:16Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
title Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
spellingShingle Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
Gomes, Luis Eduardo Miani
Crohn’s Disease
Infliximab
Antibody
Drug Monitoring
title_short Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
title_full Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
title_fullStr Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
title_full_unstemmed Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
title_sort Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
author Gomes, Luis Eduardo Miani
author_facet Gomes, Luis Eduardo Miani
Silva, Francesca Aparecida Ramos da
Pascoal, Lı´via Bitencourt
Ricci, Renato Lazarin
Nogueira, Guilherme
Camargo, Michel Gardere
Ayrizono, Maria de Lourdes Setsuko
Fagundes, João José
Leal, Raquel Franco
author_role author
author2 Silva, Francesca Aparecida Ramos da
Pascoal, Lı´via Bitencourt
Ricci, Renato Lazarin
Nogueira, Guilherme
Camargo, Michel Gardere
Ayrizono, Maria de Lourdes Setsuko
Fagundes, João José
Leal, Raquel Franco
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gomes, Luis Eduardo Miani
Silva, Francesca Aparecida Ramos da
Pascoal, Lı´via Bitencourt
Ricci, Renato Lazarin
Nogueira, Guilherme
Camargo, Michel Gardere
Ayrizono, Maria de Lourdes Setsuko
Fagundes, João José
Leal, Raquel Franco
dc.subject.por.fl_str_mv Crohn’s Disease
Infliximab
Antibody
Drug Monitoring
topic Crohn’s Disease
Infliximab
Antibody
Drug Monitoring
description OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) as well as the detection of anti-infliximab antibodies (ATIs) in patients with Crohn’s disease (CD). METHOD: Forty patients with CD under treatment at a tertiary center in southeastern Brazil were evaluated. Their use of infliximab was continuous and regular. We analyzed and compared the differences in the IFX and ATI levels between the patients with active CD (CDA) and those with CD in remission (CDR). RESULTS: There was no difference in the IFX level between the CDA and CDR groups (p40.05). Eighty percent of all patients had IFX levels above the therapeutic concentration (6-10 mg/mL). Two (9%) of the 22 patients with active disease and four (22.2%) of the 18 patients in remission had undetectable levels of IFX. Four (66.6%) of the six patients with undetectable levels of IFX had positive ATI levels; three of these patients were in remission, and one had active disease. In addition, the other two patients with undetectable levels of IFX presented ATI levels close to positivity (2.7 and 2.8 AU/ml). None of the patients with therapeutic or supratherapeutic IFX levels had positive ATI levels. CONCLUSIONS: The undetectable levels of IFX correlated with the detection of ATIs, which was independent of disease activity. Immunogenicity was not the main factor for the loss of response to IFX in our study, and the majority of patients in both groups (CDA and CDR) had supratherapeutic levels of IFX.
publishDate 2019
dc.date.none.fl_str_mv 2019-05-13
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/157947
10.6061/clinics/2019/e824
url https://www.revistas.usp.br/clinics/article/view/157947
identifier_str_mv 10.6061/clinics/2019/e824
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/157947/153226
https://www.revistas.usp.br/clinics/article/view/157947/153575
dc.rights.driver.fl_str_mv Copyright (c) 2019 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/xml
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 74 (2019); e824
Clinics; v. 74 (2019); e824
Clinics; Vol. 74 (2019); e824
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222764121980928